Inhibrx Biosciences, Inc.

NASDAQ:INBX

Biotechnology

Healthcare
$69.06 -2.74%

-$2.58 today

Market cap
$1.02B
Beta
3.32
P/E (TTM)
-11.0
EPS (TTM)
-$8.35
52W Low $13.97High $155.29

Volume 0.29M

Average 0.43M

INBX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Inhibrx Biosciences, Inc.NASDAQ: INBX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $24.69M fell 33.1% year over year, ahead of the -42.7% change in trailing-twelve-month research & development. Sequentially, it fell 2.6% from the prior quarter. Over 3 fiscal years it compounded at +0.9% a year.

Context

  • Research & development amounted to 8694.5% of revenue in FY2025, down 93177.0 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -33.1% holds above the trailing-twelve-month pace of -42.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$24.69M-2.6% QoQ
Last fiscal yearDec 2025
$113.03M-44.5% YoY
LTMMar 2026
$100.84M-42.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.1%——
1 year-44.5%——
3-year CAGR+0.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
113.03M USD
Year-over-year change
-44.5%
4-year CAGR
+12.2%

Research & Development vs competitors

How INBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -42.7% is the lowest of 7, against a peer median of +29.7%.
  • Research & development amounts to 7756.8% of revenue for INBX, versus a peer median of 704.5%.
INBX Competitors
Research & Development for INBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$283.32M USD+31.2%+43.9%252960.7%
GENBGenerate Biomedicines, Inc.FY2025$224.7M USD+28.2%—704.5%
IMTXImmatics N.V.LTM Mar 2026€201.11M EUR+27.4%+19.9%539.2%
JANXJanux Therapeutics, Inc.LTM Mar 2026$127.65M USD+60.8%+33.1%590.6%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$100.84M USD-42.7%+0.9%7756.8%
ABSIAbsci CorporationLTM Mar 2026$84.33M USD+24.0%+11.4%4593.1%
TECXTectonic Therapeutic, Inc.LTM Mar 2026$71.32M USD+63.7%+35.3%—
Peer median (excluding INBX) —+29.7%+33.1%704.5%

Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.13M2.19M1.8M200K1.3M
Cost of Revenue2.69M110.19M1.19M2.29M2.48M
Gross Profit4.44M(107.99M)609K(2.09M)(1.18M)
Gross Margin62.3%-4926.7%33.8%-1042.5%-91.0%
Research & Development71.44M110.19M190.65M203.74M113.03M
Selling, General & Admin12.36M21.12M29.38M127.91M23.3M
Operating Expenses12.34M21.12M219.83M329.36M133.84M
Depreciation & Amortization1.2M1.23M1.19M2.29M2.48M
EBITDA(75.37M)(125.82M)(206.69M)1.7B(132.54M)
EBITDA Margin-1057.8%-5739.8%-11482.9%851675.0%-10195.5%
Operating Income(76.56M)(129.12M)(219.22M)(331.45M)(135.03M)
Operating Margin-1074.6%-5890.4%-12178.9%-165724.0%-10386.5%
Interest Income5.22M16.11M11.92M10.94M7.55M
Interest Expense5.22M16.11M31.84M13.49M12.2M
Other Income / Expenses(5.2M)(16.11M)(20.5M)2.02B(5.03M)
Income Before Tax(81.77M)(145.22M)(239.72M)1.69B(140.05M)
Pre-Tax Margin-1147.6%-6625.1%-13318.0%843787.0%-10773.3%
Income Tax Expense2K3K3K2K2K
Net Income(81.77M)(145.23M)(241.36M)1.69B(140.06M)
Net Margin-1147.6%-6625.3%-13408.9%843786.0%-10773.5%
EPS (Basic)(2.15)(3.62)(5.12)116.58(9.04)
EPS (Diluted)(2.15)(3.62)(5.12)116.58(9.04)
Weighted Avg Shares38.01M40.11M47.13M14.48M15.49M
Weighted Avg Shares (Diluted)38.01M40.11M47.13M14.48M15.49M

Inhibrx Biosciences, Inc.

NASDAQ:INBX

Intrinsic Alpha fair value

Locked

Current Price

$69.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.